References
- van Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM 93(2), 105–111 (2000).
- Hanaoka BY, Peterson CA, Horbinski C, Crofford LJ. Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat. Rev. Rheumatol. 8(8), 448–457 (2012).
- Curtis JR, Westfall AO, Allison J et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 55(3), 420–426 (2006).
- Fardet L, Cabane J, Kettaneh A, Lebbé C, Flahault A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology 46(7), 1102–1106 (2007).
- Gunnar BJ, Andersson M et al. The Burden of Musculoskeletal Diseases. American Academy of Orthopaedic Surgeons, IL, USA (2008).
- van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 39(12), 1383–1389 (2000).
- Gran JT, Nordvåg BY. Referrals from general practice to an outpatient rheumatology clinic: disease spectrum and analysis of referral letters. Clin. Rheumatol. 19(6), 450–454 (2000).
- Hasselgren PO, Fischer JE. Counter-regulatory hormones and mechanisms in amino acid metabolism with special reference to the catabolic response in skeletal muscle. Curr. Opin. Clin. Nutr. Metab. Care 2(1), 9–14 (1999).
- Schakman O, Gilson H, Kalista S, Thissen JP. Mechanisms of muscle atrophy induced by glucocorticoids. Horm. Res. 72(Suppl. 1), 36–41 (2009).
- Schakman O, Dehoux M, Bouchuari S et al. Role of IGF-I and TNF-α/NF-κB pathway in the induction of muscle atrogenes by acute inflammation. Am. J. Physiol. Endocrinol. Metab. 303(6), E729–E739 (2012).
- Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int. J. Cardiol. 85(1), 89–99 (2002).
- Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 43(10), 1219–1223 (2004).
- Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 41(1), 22–26 (2002).
- Lundberg IE. Idiopathic inflammatory myopathies: why do the muscles become weak? Curr. Opin. Rheumatol. 13(6), 457–460 (2001).
- Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone. Spine 78(1), 41–44 (2011).
- Dekhuijzen PN, Gayan-Ramirez G, Bisschop A, De Bock V, Dom R, Decramer M. Corticosteroid treatment and nutritional deprivation cause a different pattern of atrophy in rat diaphragm. J. Appl. Physiol. 78(2), 629–637 (1995).
- Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve 23(12), 1785–1788 (2000).
- Douglass JA, Tuxen DV, Horne M et al. Myopathy in severe asthma. Am. Rev. Respir. Dis. 146(2), 517–519 (1992).
- Dhand UK. Clinical approach to the weak patient in the intensive care unit. Respir. Care 51(9), 1024–1040; discussion 1040 (2006).
- Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. Lancet Neurol. 10(10), 931–941 (2011).
- Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann. Neurol. 40(4), 645–654 (1996).